Ckd Bio (063160.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7063160006
Ckd Bio financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 171.76 bn KRW | 160.07 bn KRW |
| Gross profit | 35.94 bn KRW | 28.78 bn KRW |
| Operating income | 10.95 bn KRW | 3.61 bn KRW |
| EBIT | 14.48 bn KRW | 2.65 bn KRW |
| Net income | 8.70 bn KRW | -2.89 bn KRW |
| Diluted EPS – continuing operations | 1,586.02 KRW | -526.50 KRW |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
More stocks
- Mospec Semiconductor Corp (2434.TW)
- Man Zai Industrial Co Ltd (4543.TWO)
- Gain Therapeutics, Inc. (GANX)
- Leef Brands Inc. (LEEEF)
- Coheris SA (COH.PA)
- Kuangli Photoelectric Technology Co Ltd (6431.TW)
- Endurance Gold Corp (EDG.V)
- Duck Yang Ind (024900.KS)
- Rubicon Technology Inc (RBCN)
- DSR Corp (155660.KS)
- Berkah Prima Perkasa Tbk PT (BLUE.JK)
- Woojinntec Inc. (457550.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.